Mark Watson

1.2k citations
6 papers · 967 · 1 hit paper · h-index 5

Impact in

    • Cell death mechanisms and regulation
    • RNA Interference and Gene Delivery
    • Mitochondrial Function and Pathology
    • Ubiquitin and proteasome pathways
    • ATP Synthase and ATPases Research
    • Cancer-related Molecular Pathways

Papers in

    • Cell death mechanisms and regulation 3
    • Ubiquitin and proteasome pathways 3
    • Protein Structure and Dynamics 1
    • Glycosylation and Glycoproteins Research 1
    • Cancer-related Molecular Pathways 2

Mark Watson

6 papers receiving 956 citations

Hit Papers

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis 2007 · 538 citations
5380+6+12Years since publication100200300400500

Peers

Mark Watson
Comparison fields: 5 of 89
  • Molecular Biology 752
  • Oncology 200
  • Genetics 74
  • Hematology 64
  • Toxicology 19
Replace Richard A. Norman with:
Richard A. Norman United Kingdom
Xavier Billot Canada
Bainan Wu United States
Michael N. Greco United States
Robert A. Galemmo United States
Brad O. Buckman United States
David M. Ryckman United States
Susan Pav United States
Shie-Pon Tzung United States
Wen‐Hsing Lin Taiwan
Mark Watson relative to Richard A. Norman United Kingdom Richard A. Norman's profile →
Citations per field
00.5×1.5×
Richard A. Norman · 1×
Citations per year

Countries citing papers authored by Mark Watson

Since Specialization
Citations

This map shows the geographic impact of Mark Watson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Watson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Watson more than expected).

Fields of papers citing papers by Mark Watson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Watson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Watson. The network helps show where Mark Watson may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Watson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Watson Line = papers co-authored together Mark Watson links everyone, so they are left out of the graph.

All Works

6 of 6 papers shown
#Work
1
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis
Hit paper breakdown →
2007538
2 2006192
3 200596
4 199772
5 199765
6 20064

About Mark Watson

Mark Watson is a scholar working on Molecular Biology, Oncology, Infectious Diseases, Pharmacology and Epidemiology, having authored 6 papers that have together received 967 indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (3 papers), Ubiquitin and proteasome pathways (3 papers), Cancer-related Molecular Pathways (2 papers), Calpain Protease Function and Regulation (1 paper), Enzyme Structure and Function (1 paper), Protein Structure and Dynamics (1 paper), Glycosylation and Glycoproteins Research (1 paper) and HIV/AIDS drug development and treatment (1 paper). The work is most often cited by research in Molecular Biology (752 citations), Oncology (200 citations), Genetics (74 citations), Hematology (64 citations) and Toxicology (19 citations). Mark Watson has collaborated with scholars based in Canada, Australia and Spain. Frequent co-authors include Gordon C. Shore, Stéphane Acoca, Xavier Billot, Leonie A. Cluse, Lucile Serfass, Qian Liu, Richard Marcellus, Laurent Bélec, S.R. Murthy Madiraju and Tudor Moldoveanu. Their work appears in journals such as Molecular Cell, Journal of Biomolecular NMR, FEBS Letters, Clinical Pharmacokinetics and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact